Rare drug royalties, life sciences backed deals hit ABS primary

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Rare drug royalties, life sciences backed deals hit ABS primary

pills
colorful pills and tablets on background | DimaSobko/dimasobko - Fotolia

A pair of pharmaceutical and healthcare ABS offerings tested investors’ appetites for a range of esoteric ABS assets following the US Memorial Day weekend.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article